Brief: Armata Pharmaceuticals Announces Clearance Of IND For Prosthetic Joint Infections
01/08/2022 13:06
Aug 1 (Reuters) - Armata Pharmaceuticals Inc ARMP.A :
* ARMATA PHARMACEUTICALS ANNOUNCES CLEARANCE OF IND FOR
PROSTHETIC
JOINT INFECTIONS
* ARMATA PHARMACEUTICALS INC - SECOND INDICATION FOR AP-SA02
WHICH
TARGETS STAPHYLOCOCCUS AUREUS INCLUDING MRSA
* ARMATA PHARMACEUTICALS INC - POTENTIAL TO SIGNIFICANTLY
IMPROVE
PJI PATIENT OUTCOMES
Source text for Eikon: ID:nPn6JztYla
Further company coverage: ARMP.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Armata Pharmaceuticals
See all newsBrief: Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles